Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type


ABBOTT LABS   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period2021202020192018201720162015201420132012
Period End Date12/31/202112/31/202012/31/201912/31/201812/31/201712/31/201612/31/201512/31/201412/31/201312/31/2012
Net Sales43,075.0034,608.0031,904.0030,578.0027,390.0020,853.0020,405.0020,247.0019,657.0019,050.00
Total Revenues43,075.0034,608.0031,904.0030,578.0027,390.0020,853.0020,405.0020,247.0019,657.0019,050.00
Cost of Products Sold18,537.0015,003.0013,231.0012,706.0012,409.009,094.008,747.009,218.009,193.008,899.00
Amortization of intangible assets2,047.002,132.001,936.002,178.001,975.00550.00601.00555.00588.00595.00
Research and development2,742.002,420.002,440.002,300.002,260.001,447.001,405.001,345.001,371.001,461.00
Acquired in-process research and development--------------------
Selling, general and administrative11,324.009,696.009,765.009,744.009,182.006,736.006,785.006,530.006,372.006,735.00
Gain on sale of business--------------------
Total Operating Cost and Expenses34,650.0029,251.0027,372.0026,928.0025,826.0017,827.0017,538.0017,648.0017,524.0017,690.00
Operating earnings8,425.005,357.004,532.003,650.001,564.003,026.002,867.002,599.002,133.001,360.00
Interest expense533.00546.00670.00826.00904.00431.00163.00150.00145.00320.00
Interest income43.0046.0094.00105.00124.0099.00105.0077.0067.0059.00
Other income (expense), net277.00103.00191.00139.001,413.00(786.00)281.00(14.00)32.001.00
Net foreign exchange gain (loss)(1.00)8.00(7.00)(28.00)34.00(495.00)93.0024.00(46.00)31.00
Income (Loss) from TAP Pharmaceutical Products Inc. joint venture--------------------
Gain (loss) on extinguishment of debt----(63.00)(167.00)------(18.00)0.00(1,351.00)
Earnings before taxes8,211.004,968.004,077.002,873.002,231.001,413.003,183.002,518.002,041.00(220.00)
Current:U.S. Federal and Possessions859.0039.00291.00(812.00)2,260.0071.0064.0027.004.00(44.00)
Current-State--------------------
Current- Foreign790.00566.00590.00606.00508.00406.00220.00468.00482.00819.00
Deferred:Domestic(355.00)(18.00)(305.00)832.00(679.00)(147.00)313.00298.00(308.00)(572.00)
Deferred- Foreign(154.00)(90.00)(186.00)(87.00)(211.00)20.00(20.00)4.00(125.00)(660.00)
Deferred:Enacted tax rate changes--------------------
Taxes on earnings1,140.00497.00390.00539.001,878.00350.00577.00797.0053.00(457.00)
Income (loss) from Continuing Operations7,071.004,471.003,687.002,334.00353.001,063.002,606.001,721.001,988.00237.00
Earnings (Loss) from Discontinued Operations, net of taxes--24.00--34.00124.00321.0065.00563.00588.005,726.00
Gain on sale of discontinued operations, net of tax----------16.001,752.000.00----
Net earnings allocable to Common Units7,071.004,495.003,687.002,368.00477.001,400.004,423.002,284.002,576.005,963.00
Earnings Per Share (Basic) - Cont Ops3.972.512.071.320.200.711.731.131.270.15
EPS (Basic) : Disc Ops--0.01--0.020.070.231.210.370.373.61
Basic earnings per common share3.972.522.071.340.270.942.941.501.643.76
Earnings Per Share (Diluted) - Cont Ops3.942.492.061.310.20--1.721.121.260.15
Earnings Per Share (Diluted) - Disc Ops--0.01--0.020.070.231.200.370.363.57
Diluted earnings per common share3.942.502.061.330.270.942.921.491.623.72
Average Number of Common Shares Outstanding (Basic)1,775.001,773.001,768.001,758.001,740.001,477.001,496.001,516.001,558.001,575.00
Average Number of Common Shares Outstanding (Diluted)1,789.001,786.001,781.001,770.001,749.001,483.001,506.001,527.001,574.001,592.00